Immunome (NASDAQ:IMNM) Coverage Initiated by Analysts at Lifesci Capital

Investment analysts at Lifesci Capital initiated coverage on shares of Immunome (NASDAQ:IMNM - Get Free Report) in a note issued to investors on Tuesday,Benzinga reports. The brokerage set an "outperform" rating and a $20.00 price target on the stock. Lifesci Capital's target price indicates a potential upside of 125.99% from the stock's current price.

Several other equities analysts also recently issued reports on the company. Piper Sandler reduced their price objective on Immunome from $23.00 to $21.00 and set an "overweight" rating for the company in a research report on Thursday, November 14th. Wedbush reiterated an "outperform" rating and set a $33.00 price target on shares of Immunome in a research report on Monday. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $27.17.

Immunome Stock Down 5.2 %

Immunome stock opened at $8.85 on Tuesday. Immunome has a 52-week low of $8.51 and a 52-week high of $26.70. The firm has a market capitalization of $706.03 million, a price-to-earnings ratio of -1.09 and a beta of 1.93. The firm has a 50-day moving average price of $10.13 and a two-hundred day moving average price of $11.94.

Insiders Place Their Bets

In other news, CEO Clay B. Siegall acquired 150,000 shares of the company's stock in a transaction dated Friday, January 31st. The shares were bought at an average price of $7.75 per share, with a total value of $1,162,500.00. Following the purchase, the chief executive officer now owns 669,636 shares of the company's stock, valued at approximately $5,189,679. This represents a 28.87 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 8.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of IMNM. Charles Schwab Investment Management Inc. lifted its holdings in Immunome by 217.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company's stock valued at $6,469,000 after acquiring an additional 302,916 shares during the last quarter. Victory Capital Management Inc. lifted its stake in Immunome by 48.1% during the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company's stock valued at $10,684,000 after purchasing an additional 237,497 shares during the last quarter. Geode Capital Management LLC lifted its stake in Immunome by 13.6% during the third quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company's stock valued at $17,657,000 after purchasing an additional 144,557 shares during the last quarter. Magnus Financial Group LLC boosted its holdings in Immunome by 107.8% during the fourth quarter. Magnus Financial Group LLC now owns 53,536 shares of the company's stock worth $569,000 after buying an additional 27,777 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its position in Immunome by 22.2% in the third quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company's stock worth $6,881,000 after buying an additional 85,580 shares during the last quarter. Institutional investors own 44.58% of the company's stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads